Roche presents new data from its bispecific antibody portfolio across a range of blood cancers

NEXT STORY
Scottish Medicines Consortium approves Lupin’s NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
PREV STORY
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Healixa Inc. to Establish Nationally Recognized Medical Advisory Committee

author_avatar
NASDAQ Market News

iBio Announces Pricing of $35 Million Public Offering of Common Stock

author_avatar
NASDAQ Market News

Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform

author_avatar
NASDAQ Market News